Although Cldn3 and Cldn4 have been shown to be expressed in prostate cancers, and was the focus of CPE intervention, targeting Cldn3 and Cldn4 expression in relation to prostate cancer cell survival rates has not been investigated. The gene discussed is CLDN4; the disease is prostate carcinoma.